23andMe
Search results
6 days ago · Experience with DNAnexus and Nextflow would be an advantage. 2. As the Bioinformatician you will be responsible for preparing, supporting and guiding (leadership where relevant) new target identification, target validation, biomarker discovery and patient stratification through the functional interpretation of omics data and knowledge databases.
Jul 4, 2024 · Updated 1 hour ago. The UKB-RAP is a cloud-based platform that provides a secure environment for researchers to access UK Biobank’s data. It holds a complete copy of UK Biobank’s data and provides access to storage, compute, and analysis resources so researchers can undertake their analyses within the platform. We created the UKB-RAP with ...
Jul 4, 2024 · PLINK 2 prefers to represent the X chromosome's pseudo-autosomal region as 'PAR1' and 'PAR2' regions; this removes the need for special handling of male X heterozygous calls. This has a major computational advantage over PLINK 1.x's 'XY' convention: splitting and remerging no longer require resorting of the variants.
Jul 5, 2024 · The registry is powered by DNAnexus’ secure, cloud bioinformatics platform for scientific data analysis, collaboration and discovery. The registry will enable clinicians to explore hypotheses in real-time by analyzing diverse de-identified patient data involving ancestry, geography, cancer diagnosis, treatment outcomes, and more.
Jul 4, 2024 · Due to funding provided by Wellcome, access to the UKB-RAP is currently free, however there are fees (payable to the platform provider, DNAnexus) for storage of uploaded or derived data, compute, analysis (dependent on the type of virtual computer you choose to use for your analysis), and egress charges for data relating to summary ...
6 days ago · Enabling scientists to understand and analyze their own experimental data by providing instruction and training in bioinformatics software, databases, analyses techniques, and emerging technologies. Upcoming Classes & Events.
Jul 6, 2024 · The Diabetes, Obesity and Complications Therapeutic Area (DOCTA) focuses on new therapeutic approaches for the treatment of diabetes, obesity and cardiometabolic diseases. Starting from an idea, we work with partners across Lilly to discover and develop novel biologic, small molecule and nucleic acid-based therapeutics.
